8XX Stock Overview
Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Ulisse Biomed S.p.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.18 |
52 Week High | €2.22 |
52 Week Low | €1.16 |
Beta | 0.57 |
1 Month Change | -15.71% |
3 Month Change | -27.83% |
1 Year Change | -41.00% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -69.13% |
Recent News & Updates
Recent updates
Shareholder Returns
8XX | DE Biotechs | DE Market | |
---|---|---|---|
7D | -8.2% | -0.2% | 0.5% |
1Y | -41.0% | -22.8% | 1.3% |
Return vs Industry: 8XX underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: 8XX underperformed the German Market which returned 2.3% over the past year.
Price Volatility
8XX volatility | |
---|---|
8XX Average Weekly Movement | 4.9% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8XX's share price has been volatile over the past 3 months.
Volatility Over Time: 8XX's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 9 | Nicola Basile | www.ulissebiomed.com |
Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases and HPV.
Ulisse Biomed S.p.A. Fundamentals Summary
8XX fundamental statistics | |
---|---|
Market cap | €26.32m |
Earnings (TTM) | -€1.68m |
Revenue (TTM) | €90.91k |
289.5x
P/S Ratio-15.7x
P/E RatioIs 8XX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
8XX income statement (TTM) | |
---|---|
Revenue | €90.91k |
Cost of Revenue | €1.06m |
Gross Profit | -€967.89k |
Other Expenses | €707.82k |
Earnings | -€1.68m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.078 |
Gross Margin | -1,064.71% |
Net Profit Margin | -1,843.32% |
Debt/Equity Ratio | 0.2% |
How did 8XX perform over the long term?
See historical performance and comparison